COCH — Envoy Medical Income Statement
0.000.00%
Last trade - 00:00- $49.63m
- $45.89m
- $0.24m
Annual income statement for Envoy Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.31 | 0.237 | 0.316 | 0.225 | 0.241 |
| Cost of Revenue | |||||
| Gross Profit | -0.459 | -0.72 | -0.473 | -0.517 | -0.633 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 7.18 | 8.94 | 18.7 | 19.5 | 22.5 |
| Operating Profit | -6.87 | -8.71 | -18.4 | -19.3 | -22.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8.68 | -15.9 | -29.9 | -20.8 | -23.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -8.68 | -15.9 | -29.9 | -20.8 | -23.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8.68 | -15.9 | -29.9 | -20.8 | -23.8 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8.68 | -15.9 | -31.3 | -28 | -28.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.444 | -0.814 | -2.54 | -1.49 | -1.23 |